Patient-Targeted Education (ePRO-E) to Increase ePRO Uptake Within an Alliance Clinical Trial (A221805-SI1)

Exploring the Role of a Dedicated Research Nurse in a National Cancer Institute Community Oncology Research Program (NCORP) Alliance Study

Safety of tepotinib + osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with mesenchymal–epithelial transition (MET) amplification following first-line osimertinib: INSIGHT 2 primary analysis

Post-progression and safety outcomes with first-line (1L) amivantamab plus lazertinib versus osimertinib in patients with advanced non-small cell lung cancer (NSCLC) with common EGFR mutations: Implications for best management practices

The Effect of Prior Docetaxel Treatment in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Apalutamide plus Androgen Deprivation Therapy (TITAN Study)

Impact of a Rash Management Protocol on Incidence and Severity of Rash with Apalutamide Patients with High-Risk Localized Prostate Cancer (Apa-RP Study)

Safety outcomes of subcutaneous nivolumab across phase 1/2 CheckMate 8KX and phase 3 Checkmate 67T studies

Presence of Homologous Recombination Repair Gene Mutations and Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving First Line Treatment (CAPTURE Study)

Treatment with Enzalutamide in Patients with High-risk Biochemically Recurrent Prostate Cancer from the EMBARK Trial: Nursing Implications

Management of adverse events associated with cabozantinib for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, or radioiodine-refractory differentiated thyroid cancer

Management of adverse events associated with cabozantinib plus nivolumab in advanced renal cell carcinoma

CARTITUDE-2 Long-Term Efficacy and Safety of Ciltacabtagene Autoleucel for Patients With Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and With Early Relapse (Cohort B)

Final Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations Receiving First-Line Niraparib with Abiraterone Acetate plus Prednisone (MAGNITUDE Study)

Patient-Reported Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer and BRCA1/2 Mutations Receiving First-Line Niraparib with Abiraterone Acetate plus Prednisone (MAGNITUDE Study)

Impact of socioeconomic disadvantage on symptom duration, treatment initiation, and survival among primary brain tumor patients: A large cohort analysis